Setting the Scene for Novel Combination Partner Approaches for Vedotin-Based ADCs Including PADCEV
- Contextualizing the significance of combination approaches within the future of ADC patient impact in early-line oncology therapies
- Laying out the transformative clinical performance of Padcev-Keyruda combination including event free survival in MIBC
- Addressing the need and opportunity for novel combinations partners to enhance Padcev clinical impact